Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[F-18]-5-fluoro-2'-deoxycytidine
- Development stage
- Phase 1
- Lead developer
- National Cancer Institute
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[F-18]-5-fluoro-2'-deoxycytidine is a radiolabeled analog of the investigational anticancer agent 5-fluoro-2'-deoxycytidine (FdCyd), in which the fluorine atom at position 5 of the cytidine ring is replaced with radioactive fluorine‑18. It is used as a positron emission tomography (PET) imaging agent to noninvasively assess biodistribution and tumor uptake of FdCyd in patients, particularly those undergoing therapy with nonradioactive FdCyd. The parent compound, FdCyd, acts as an inhibitor of DNA methyltransferase (DNMT), suppressing epigenetic hypermethylation in tumor cells and thereby exerting antitumor effects. As a prodrug, it can also be converted intracellularly to cytotoxic metabolites such as 5-fluorouracil[4][6]. The radiolabeled form ([F‑18]FdCyd) enables visualization and quantification of drug delivery to tumors via PET/CT imaging[6][8].
- Other names
- 18F-FdCydF-18 FdCydF18 FdCydF 18 FdCyd[^18F]FdCyd
02
Targets
DNMT1 (DNA (cytosine-5)-methyltransferase 1)
Beyond the preview
Go deeper on [F-18]-5-fluoro-2'-deoxycytidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [F-18]-5-fluoro-2'-deoxycytidine.